Compare iShares Bitcoin Trust (IBIT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares Bitcoin Trust trades at $45.5 (market cap $66.80B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: iShares Bitcoin Trust is far larger — about 68.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 42 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IBIT | MRVI | |
|---|---|---|
Market Cap | $66.80B | $977.37M |
Volume | 40,279,711 | 2,742,564 |
Sector | Crypto-linked | Health |
52-Week High | $65.28 | $9.00 |
52-Week Low | $33.29 | $2.83 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.13, up 0.58% with neutral technical signals. The stock shows bullish moving average momentum but faces resistance at $48. Recent inflows of $196 million on October 1, 2026, highlight renewed institutional interest in BlackRock's ETF offerings, though financial ratios remain undisclosed.
Outlook remains balanced with technical support at $46-$47. Key risks include market volatility and regulatory uncertainty. Analyst sentiment is mixed, with institutional flows suggesting cautious optimism amid broader crypto ETF market resilience.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
